Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials
Emmanuel Mignot, David Mayleben, Ingo Fietze, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 2, pp. 125-139
Closed Access | Times Cited: 145

Showing 1-25 of 145 citing articles:

The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
Dieter Riemann, Colin A. Espie, Ellemarije Altena, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 216
Associations of sleep disorders with all-cause MCI/dementia and different types of dementia – clinical evidence, potential pathomechanisms and treatment options: A narrative review
Geert Mayer, Helmut Frohnhofen, Martha Jokisch, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 18
Clinical practice guidelines for switching or deprescribing hypnotic medications for chronic insomnia: results of European neuropsychopharmacology and sleep expert’s consensus group
Laura Palagini, Roberto Brugnoli, Bernardo M Dell' Osso, et al.
Sleep Medicine (2025) Vol. 128, pp. 117-126
Closed Access | Times Cited: 2
Daridorexant: First Approval
Anthony Markham
Drugs (2022) Vol. 82, Iss. 5, pp. 601-607
Open Access | Times Cited: 56
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Dieter Kunz, Yves Dauvilliers, Heike Beneš, et al.
CNS Drugs (2022) Vol. 37, Iss. 1, pp. 93-106
Open Access | Times Cited: 52
The orexin story, sleep and sleep disturbances
Fabio Pizza, Lucie Barateau, Yves Dauvilliers, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 48
FDA-Approved Small Molecules in 2022: Clinical Uses and Their Synthesis
Davide Benedetto Tiz, Luana Bagnoli, Ornelio Rosati, et al.
Pharmaceutics (2022) Vol. 14, Iss. 11, pp. 2538-2538
Open Access | Times Cited: 47
The orexin story and orexin receptor antagonists for the treatment of insomnia
Clemens Muehlan, Catherine Roch, Cédric Vaillant, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 39
New Approved Drugs Appearing in the Pharmaceutical Market in 2022 Featuring Fragments of Tailor-Made Amino Acids and Fluorine
Nana Wang, Haibo Mei, Gagan Dhawan, et al.
Molecules (2023) Vol. 28, Iss. 9, pp. 3651-3651
Open Access | Times Cited: 29
Insomnia Management: A Review and Update
David Shaha
The Journal of Family Practice (2023) Vol. 72, Iss. 06 Supp
Open Access | Times Cited: 29
Current models of insomnia disorder: a theoretical review on the potential role of the orexinergic pathway with implications for insomnia treatment
Laura Palagini, Pierre A. Geoffroy, Matteo Balestrieri, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 4
Closed Access | Times Cited: 25
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Assessing the Risk of Bias in Randomized Clinical Trials With Large Language Models
Honghao Lai, Long Ge, Mingyao Sun, et al.
JAMA Network Open (2024) Vol. 7, Iss. 5, pp. e2412687-e2412687
Open Access | Times Cited: 14
Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial
Ingo Fietze, Claudio L. Bassetti, David Mayleben, et al.
Drugs & Aging (2022) Vol. 39, Iss. 10, pp. 795-810
Open Access | Times Cited: 32
The Comparative Effectiveness and Safety of Insomnia Drugs: A Systematic Review and Network Meta-Analysis of 153 Randomized Trials
Bei Pan, Long Ge, Honghao Lai, et al.
Drugs (2023) Vol. 83, Iss. 7, pp. 587-619
Closed Access | Times Cited: 18
Alliance for Sleep Clinical Practice Guideline on Switching or Deprescribing Hypnotic Medications for Insomnia
Nathaniel F. Watson, Ruth M. Benca, Andrew D. Krystal, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 7, pp. 2493-2493
Open Access | Times Cited: 18
New drug approvals for 2022: Synthesis and clinical applications
Shuo Yuan, Dandan Shen, Rui Jia, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 6, pp. 2352-2391
Closed Access | Times Cited: 18
Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care
Jason Ellis, Luigi Ferini‐Strambi, Diego García‐Borreguero, et al.
Healthcare (2023) Vol. 11, Iss. 5, pp. 716-716
Open Access | Times Cited: 17
The importance and limitations of polysomnography in insomnia disorder—a critical appraisal
Lukas Frase, Christoph Nissen, Kai Spiegelhalder, et al.
Journal of Sleep Research (2023) Vol. 32, Iss. 6
Open Access | Times Cited: 16
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Post-traumatic stress disorder: the role of the amygdala and potential therapeutic interventions – a review
Lori L. Davis, Mark B. Hamner
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 6
Orexin Receptor Antagonism: Normalizing Sleep Architecture in Old Age and Disease
J Kron, Ryan J. Keenan, Daniël Hoyer, et al.
The Annual Review of Pharmacology and Toxicology (2023) Vol. 64, Iss. 1, pp. 359-386
Open Access | Times Cited: 15
Evaluation and management of insomnia in the clinical practice in Italy: a 2023 update from the Insomnia Expert Consensus Group
Laura Palagini, Raffaele Manni, Claudio Liguori, et al.
Journal of Neurology (2023) Vol. 271, Iss. 4, pp. 1668-1679
Closed Access | Times Cited: 13
Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials
Andrea Phillips-Beyer, Ariane K. Kawata, Leah Kleinman, et al.
Pharmaceutical Medicine (2024) Vol. 38, Iss. 2, pp. 133-144
Open Access | Times Cited: 5
Orexinergic Receptor Antagonists as a New Therapeutic Target to Overcome Limitations of Current Pharmacological Treatment of Insomnia Disorder
Cecilio Álamo, Jerónimo Sáiz Ruiz, Cristina Zaragozá Arnáez
Actas Españolas de Psiquiatría (2024) Vol. 52, Iss. 2, pp. 172-182
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top